(Q47910873)

English

A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort.

scientific article published on 12 June 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23895407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23895407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Olivier Outteryck

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23895407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Christine Lebrun-Frenay

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23895407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23895407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Jean-Christophe Ouallet

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23895407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Pierre Clavelou

26

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23895407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

36

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23895407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

author name string

J C Ongagna

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23895407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

B Brochet

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23895407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

L Rumbach

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23895407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

M Debouverie

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23895407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

E Berger

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23895407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

M Cohen

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23895407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

S Pittion

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23895407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

D Laplaud

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23895407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

S Wiertlewski

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23895407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

P Cabre

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23895407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

J Pelletier

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23895407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

A Rico

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23895407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

G Defer

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23895407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

N Derache

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23895407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

W Camu

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23895407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

E Thouvenot

20

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23895407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

T Moreau

21

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23895407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

A Fromont

22

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23895407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

A Tourbah

23

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23895407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

P Labauge

24

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23895407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

G Castelnovo

25

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23895407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

O Casez

27

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23895407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

P Hautecoeur

28

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23895407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

C Papeix

29

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23895407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

C Lubetzki

30

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23895407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

B Fontaine

31

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23895407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

N Couturier

32

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23895407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

N Bohossian

33

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23895407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

M Clanet

34

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23895407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

P Vermersch

35

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23895407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

D Brassat

37

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23895407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

BIONAT Network,

38

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23895407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

CFSEP

39

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23895407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

publication date

12 June 2013

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23895407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

European Journal of Neurology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23895407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

21

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23895407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23895407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

40-48

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23895407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1111%2FENE.12204

21 January 2018

Freedom from disease activity in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1111%2FENE.12204

21 January 2018

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

1 reference

https://api.crossref.org/works/10.1111%2FENE.12204

21 January 2018

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.

1 reference

https://api.crossref.org/works/10.1111%2FENE.12204

21 January 2018

Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice.

1 reference

https://api.crossref.org/works/10.1111%2FENE.12204

21 January 2018

The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study.

1 reference

https://api.crossref.org/works/10.1111%2FENE.12204

21 January 2018

Three years of experience: the Italian registry and safety data update.

1 reference

https://api.crossref.org/works/10.1111%2FENE.12204

21 January 2018

Swedish natalizumab (Tysabri) multiple sclerosis surveillance study

1 reference

https://api.crossref.org/works/10.1111%2FENE.12204

21 January 2018

Treatment effect of natalizumab on relapse outcomes in multiple sclerosis patients despite ongoing MRI activity.

1 reference

https://api.crossref.org/works/10.1111%2FENE.12204

21 January 2018

Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1111%2FENE.12204

21 January 2018

Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors

1 reference

https://api.crossref.org/works/10.1111%2FENE.12204

21 January 2018

Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1.

1 reference

https://api.crossref.org/works/10.1111%2FENE.12204

21 January 2018

Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy

1 reference

https://api.crossref.org/works/10.1111%2FENE.12204

21 January 2018

Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort

1 reference

https://api.crossref.org/works/10.1111%2FENE.12204

21 January 2018

Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort

1 reference

https://api.crossref.org/works/10.1111%2FENE.12204

21 January 2018

The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.

1 reference

https://api.crossref.org/works/10.1111%2FENE.12204

21 January 2018

Risk of natalizumab-associated progressive multifocal leukoencephalopathy

1 reference

https://api.crossref.org/works/10.1111%2FENE.12204

21 January 2018

Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1111%2FENE.12204

21 January 2018

B-cell subsets up-regulate α4 integrin and accumulate in the cerebrospinal fluid in clinically isolated syndrome suggestive of multiple sclerosis onset.

1 reference

https://api.crossref.org/works/10.1111%2FENE.12204

21 January 2018

Immunological markers of optimal response to natalizumab in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1111%2FENE.12204

21 January 2018

Defining the response to interferon-β in relapsing-remitting multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1111%2FENE.12204

21 January 2018

Identifiers

10.1111/ENE.12204

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23895407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

release_dif6tyjc7jbm3i5y3exrbh6g4a

1 reference

https://api.fatcat.wiki/v0/release/dif6tyjc7jbm3i5y3exrbh6g4a

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23895407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47910873&oldid=1842986253"